NEW YORK, Dec. 27, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Innovative Industrial Properties, Inc. (“IIPR” or the “Company”) (NYSE: IIPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980….
Tag: PR Newswire
NEW YORK, Dec. 27, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Innovative Industrial Properties, Inc. (“IIPR” or the “Company”) (NYSE: IIPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980….
NEW YORK, Dec. 27, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Innovative Industrial Properties, Inc. (“IIPR” or the “Company”) (NYSE: IIPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980….
NEW YORK, Dec. 27, 2024 /PRNewswire/ — Willow Lane Acquisition Corp. (Nasdaq: WLACU) (the “Company”) announced today that, commencing December 30, 2024, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares…
NEW YORK, Dec. 27, 2024 /PRNewswire/ — Willow Lane Acquisition Corp. (Nasdaq: WLACU) (the “Company”) announced today that, commencing December 30, 2024, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares…
NEW YORK, Dec. 27, 2024 /PRNewswire/ — Willow Lane Acquisition Corp. (Nasdaq: WLACU) (the “Company”) announced today that, commencing December 30, 2024, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares…
Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J., Dec. 27, 2024 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius Pharma” or the “Company”) (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of…
Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J., Dec. 27, 2024 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius Pharma” or the “Company”) (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of…
Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J., Dec. 27, 2024 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius Pharma” or the “Company”) (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of…
CRANFORD, N.J., Dec. 27, 2024 /PRNewswire/ — Citius Oncology, Inc. (“Citius Oncology” or the “Company”) (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial…
